Avalon GloboCare (NASDAQ:CHGA – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($3.53) earnings per share for the quarter, FiscalAI reports.
Avalon GloboCare Stock Down 16.4%
Shares of NASDAQ:CHGA opened at $0.89 on Tuesday. The company’s fifty day moving average is $1.72 and its two-hundred day moving average is $6.98. Avalon GloboCare has a 12-month low of $0.69 and a 12-month high of $37.65. The company has a market cap of $992,656.00, a P/E ratio of -0.06 and a beta of -0.15.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Avalon GloboCare has an average rating of “Sell”.
Check Out Our Latest Report on Avalon GloboCare
Avalon GloboCare Company Profile
Avalon GloboCare is a biotechnology and healthcare company whose activities have included developing cell-based therapies and precision diagnostic technologies. Its research has focused on applications in areas such as cancer and regenerative medicine. The company has worked on cell therapy approaches, including CAR-T and natural killer cell technologies, as well as diagnostic products and services. These activities have included research and development programs, rather than a broad portfolio of established therapies.
Read More
- Five stocks we like better than Avalon GloboCare
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
Receive News & Ratings for Avalon GloboCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon GloboCare and related companies with MarketBeat.com's FREE daily email newsletter.
